Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

16 mai 2017 16h05 HE | Source: Conatus Pharmaceuticals Inc.

Conatus Announces Completion of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

SAN DIEGO, May 16, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver...
11 mai 2017 09h01 HE | Source: Conatus Pharmaceuticals Inc.

Conatus Announces Pricing of Public Offering of Common Stock

SAN DIEGO, May 11, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver...
10 mai 2017 16h01 HE | Source: Conatus Pharmaceuticals Inc.

Conatus Announces Proposed Public Offering of Common Stock

SAN DIEGO, May 10, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver...
04 mai 2017 16h05 HE | Source: Conatus Pharmaceuticals Inc.

Conatus Pharmaceuticals Reports First Quarter 2017 Financial Results and Program Updates

SAN DIEGO, May 04, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced financial results for the first quarter ended March 31, 2017, and provided updates on its...
04 mai 2017 01h15 HE | Source: Conatus Pharmaceuticals Inc.

Conatus Announces Exercise of License Option for Global Development and Commercialization of Emricasan Following Notice of Initiation of Phase 2b ENCORE-LF Clinical Trial in NASH Cirrhosis

SAN DIEGO, May 04, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced that Novartis has exercised its option to an exclusive license for the global development and...
27 avr. 2017 16h05 HE | Source: Conatus Pharmaceuticals Inc.

Conatus Pharmaceuticals to Report First Quarter 2017 Financial Results

SAN DIEGO, April 27, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced that it will report financial results for the first quarter ended March 31, 2017, after the...
21 avr. 2017 02h00 HE | Source: Conatus Pharmaceuticals Inc.

Conatus Posters at EASL Meeting Address MELD Score Dynamics and Outcomes in Decompensated Liver Cirrhosis Patients, Including NASH Patients, Awaiting Liver Transplantation

AMSTERDAM, the Netherlands, April 21, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) announced that two posters co-authored by Conatus employees are being presented today at The...
27 mars 2017 07h30 HE | Source: Conatus Pharmaceuticals Inc.

Conatus to Present at Upcoming Investor Conferences

SAN DIEGO, March 27, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced the company’s scheduled presentations at two upcoming investor conferences in New York: H.C....
15 mars 2017 16h05 HE | Source: Conatus Pharmaceuticals Inc.

Conatus Pharmaceuticals Reports 2016 Financial Results and Program Updates

SAN DIEGO, March 15, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced financial results for the fourth quarter and full year ended December 31, 2016, and provided...
08 mars 2017 16h05 HE | Source: Conatus Pharmaceuticals Inc.

Conatus Pharmaceuticals to Report Fourth Quarter and Full Year 2016 Financial Results

SAN DIEGO, March 08, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced that it will report financial results for the fourth quarter and full year ended December 31,...

Page précédente

Page suivante